Saad F - Search Results

1

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND. Dearnaley DP, et al. Among authors: saad f. Eur Urol. 2020 Aug;78(2):184-192. doi: 10.1016/j.eururo.2020.03.001. Epub 2020 Apr 6. Eur Urol. 2020. PMID: 32273183 Free article. Clinical Trial.

2

Role of bisphosphonates in prostate cancer.

Saad F, Schulman CC. Saad F, et al. Eur Urol. 2004 Jan;45(1):26-34. doi: 10.1016/j.eururo.2003.10.003. Eur Urol. 2004. PMID: 14667511 Review.

3

Bone health in men with prostate cancer: diagnostic and therapeutic considerations.

Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI. Saad F, et al. Can J Urol. 2005 Jun;12 Suppl 2:9-15. Can J Urol. 2005. PMID: 16018826 Review.

4

Validation of prostate cancer index and SF-12 short forms.

Lebeau T, Perrotte P, Valiquette L, Bénard F, McCormack M, Saad F, Karakiewicz PI. Lebeau T, et al. Among authors: saad f. Can J Urol. 2005 Dec;12(6):2873-9. Can J Urol. 2005. PMID: 16401372

5

Natural history and treatment of bone complications in prostate cancer.

Saad F, Clarke N, Colombel M. Saad F, et al. Eur Urol. 2006 Mar;49(3):429-40. doi: 10.1016/j.eururo.2005.12.045. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16431012 Review.

6

Therapeutic approach to hormone-refractory prostate cancer.

Saad F, Al Dejmah A, Perrotte P, McCormack M, Bénard F, Valiquette L, Karakiewicz PI. Saad F, et al. Can J Urol. 2006 Apr;13 Suppl 2:52-6. Can J Urol. 2006. PMID: 16672130 Review.

7

Sunitinib relieves renal cell carcinoma spinal cord compression.

Trinh QD, Cardinal E, Gallina A, Perrotte P, Saad F, Karakiewicz PI. Trinh QD, et al. Among authors: saad f. Eur Urol. 2007 Jun;51(6):1741-3. doi: 10.1016/j.eururo.2006.10.050. Epub 2006 Nov 3. Eur Urol. 2007. PMID: 17126991

8

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB; Atrasentan Phase III Study Group Institutions. Carducci MA, et al. Among authors: saad f. Cancer. 2007 Nov 1;110(9):1959-66. doi: 10.1002/cncr.22996. Cancer. 2007. PMID: 17886253 Free article. Clinical Trial.

9

Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.

Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Jeldres C, et al. Among authors: saad f. Eur Urol. 2008 Jul;54(1):107-16. doi: 10.1016/j.eururo.2007.10.038. Epub 2007 Oct 30. Eur Urol. 2008. PMID: 17996358

10

High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.

Jeldres C, Suardi N, Saad F, Montorsi F, Shariat SF, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. Jeldres C, et al. Among authors: saad f. Eur Urol. 2008 Jul;54(1):97-105. doi: 10.1016/j.eururo.2007.10.070. Epub 2007 Nov 6. Eur Urol. 2008. PMID: 17997022

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,349 results

Search Page